Last reviewed · How we verify
AZD4017
AZD4017 is a small molecule inhibitor of the sodium-hydrogen exchanger 1 (NHE1).
AZD4017 is a small molecule inhibitor of the sodium-hydrogen exchanger 1 (NHE1). Used for Atrial fibrillation for stroke prevention.
At a glance
| Generic name | AZD4017 |
|---|---|
| Also known as | 11b-Hydroxysteroid dehydrogenase type 1 inhibitor |
| Sponsor | AstraZeneca |
| Drug class | NHE1 inhibitor |
| Target | NHE1 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
By inhibiting NHE1, AZD4017 reduces the influx of sodium ions into cardiac myocytes, which can help to prevent cardiac arrhythmias and reduce the risk of stroke in patients with atrial fibrillation.
Approved indications
- Atrial fibrillation for stroke prevention
Common side effects
- Hypotension
- Dizziness
- Headache
Key clinical trials
- Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (PHASE2)
- Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (PHASE2)
- Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (PHASE2)
- A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure (PHASE2)
- Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue (PHASE1)
- Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (PHASE1)
- Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017. (PHASE1)
- Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD4017 CI brief — competitive landscape report
- AZD4017 updates RSS · CI watch RSS
- AstraZeneca portfolio CI